Pharma BD Deal Intelligence
BioSpace highlighted CEO Henry Ji's claim that 'very few companies have the breadth of capabilities covering all facets of ADC technology,' positioning the…
ADC Review framed the deal as Sorrento securing a comprehensive ADC platform — antibody, conjugation chemistry, linker, and toxin — with David Miao stepping in…
Sorrento closed the Concortis acquisition by issuing 1,331,978 common shares (transaction valued at $11.3M based on 18-Dec close), gaining C-Lock/K-Lock…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sorrento entered definitive agreement to acquire San Diego-based Concortis Biosystems; combined Concortis conjugation platform with Sorrento's G-MAB antibody library to build next-gen ADC capability. Strategically notable platform deal.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sorrento Therapeutics Inc. / Concortis Biosystems Corp. (this deal) | 2013 | $11M | 32 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2013 deals · Oncology deals